ABEO
Bearish signalScored 2026-10-05 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Abeona Therapeutics Inc.
- Nom
- Abeona Therapeutics Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $247.3M
- Employés
- 226
- PDG
- Vishwas Seshadri
- Site web
- https://www.abeonatherapeutics.com
- Marché
- ARCTASMBELDNFHTXHUMAPBYI
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 34 608 titres (~189 057,00 $ US)
- Insiders
- Seshadri VishwasAlvino Mark
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$296,397
Avg sell (VWAP, 90d window) $5.35 vs last close $5.01 (-6.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-29
- Liquidity
- Thin $7,695,563/day · 20d vol
- Last synced
-
2026-10-06 21:10:01
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-29 | O'Malley Brendan M. | Sell · S | 6,727 | $5.16 | $34,682 | Form 4 |
| 2026-09-29 | Seshadri Vishwas | Sell · S | 19,608 | $5.16 | $101,091 | Form 4 |
| 2026-09-29 | Vasanthavada Madhav | Sell · S | 4,902 | $5.16 | $25,273 | Form 4 |
| 2026-09-29 | Vazzano Joseph Walter | Sell · S | 9,191 | $5.16 | $47,385 | Form 4 |
| 2026-09-01 | Alvino Mark | Sell · S | 15,000 | $5.86 | $87,966 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-05 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ABEO presents a mixed picture: a solid liquidity position (current ratio 6.93) and a promising accounting turnaround are materially undermined by persistently negative operating cash flow, a deeply negative interest…
The first sentence of the analysis written for ABEO on 2026-10-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 6.93 · operating margin -1537% — readings disagree
Suggested stop 4.42, nearest stored support minus 0.5 ATR(11.8% under the last close). Reward/risk to the next stored resistance is 0.12. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 73.7% | 0.0% | 54.1% | 68.2% | 100.0% | |
| Ebit Margin | 1289.1% | 0.0% | -1536.3% | -2755.3% | -2709.3% | |
| Ebitda Margin | 1350.3% | 0.0% | -1444.9% | -2431.6% | -2560.5% | |
| Operating Profit Margin | -1536.9% | 0.0% | -1346.7% | -3600.8% | -2994.5% | |
| Pretax Profit Margin | 1224.8% | 0.0% | -1548.2% | -2807.4% | -2831.2% | |
| Continuous Operations Profit Margin | 1223.1% | 0.0% | -1548.2% | -2807.4% | -2831.2% | |
| Net Profit Margin | 1223.1% | 0.0% | -1548.2% | -2807.4% | -2831.2% | |
| Bottom Line Profit Margin | 1152.5% | 0.0% | -1548.2% | -3074.8% | -2831.2% | |
| Current Ratio | 6.930 | 6.080 | 4.153 | 6.826 | 3.386 | |
| Quick Ratio | 6.744 | 6.080 | 4.153 | 6.826 | 3.386 | |
| Solvency Ratio | 1.238 | -0.937 | -1.037 | -0.938 | -2.162 | |
| Cash Ratio | 2.653 | 1.408 | 1.078 | 1.828 | 1.981 | |
| Price To Earnings Ratio | 3.933 | -3.594 | -1.980 | -0.557 | -0.395 | |
| Price To Earnings Growth Ratio | -0.021 | 0.093 | 0.037 | 0.007 | 0.072 | |
| Forward Price To Earnings Growth Ratio | -0.021 | 0.093 | 0.037 | 0.007 | 0.072 | |
| Price To Earnings Diluted Ratio | 5.218 | -3.594 | -1.980 | -0.557 | -0.395 | |
| Price To Earnings Diluted Growth Ratio | -0.032 | 0.093 | 0.037 | 0.007 | 0.072 | |
| Price To Book Ratio | 1.753 | 5.193 | 7.225 | 0.905 | 0.790 | |
| Price To Sales Ratio | 47.949 | 0.000 | 30.604 | 17.125 | 11.158 | |
| Price To Free Cash Flow Ratio | -3.310 | -3.911 | -2.869 | -0.555 | -0.479 | |
| Price To Operating Cash Flow Ratio | -3.656 | -4.082 | -2.894 | -0.557 | -0.510 | |
| Debt To Assets Ratio | 0.114 | 0.212 | 0.084 | 0.119 | 0.118 | |
| Debt To Equity Ratio | 0.157 | 0.523 | 0.364 | 0.285 | 0.221 | |
| Debt To Capital Ratio | 0.136 | 0.344 | 0.267 | 0.222 | 0.181 | |
| Long Term Debt To Capital Ratio | 0.047 | 0.228 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.379 | 2.474 | 4.317 | 2.400 | 1.878 | |
| Working Capital Turnover Ratio | 0.045 | 0.000 | 0.080 | 0.033 | 0.063 | |
| Operating Cash Flow Ratio | -2.581 | -3.377 | -2.757 | -5.590 | -3.950 | |
| Operating Cash Flow Sales Ratio | -13.114 | 0.000 | -10.574 | -30.752 | -21.888 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | 1.044 | 1.009 | 1.003 | 1.063 | |
| Debt Service Coverage Ratio | 4.917 | -5.587 | -120.986 | -46.716 | -21.011 | |
| Interest Coverage Ratio | -23.917 | -15.259 | -112.763 | -69.178 | -24.572 | |
| Short Term Operating Cash Flow Coverage Ratio | -6.245 | -9.452 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.057 | -2.430 | -6.854 | -5.701 | -7.002 | |
| Capital Expenditure Coverage Ratio | -9.571 | -22.901 | -111.810 | -334.485 | -15.819 | |
| Dividend Paid And Capex Coverage Ratio | -9.571 | -22.901 | -111.810 | -334.485 | -15.819 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 2.871 | -4.033 | -1.939 | -0.513 | -0.129 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 73.7% | ▲73.7% | ▲14.5% |
| Ebit Margin | 1289.0% | ▲1289.0% | ▲2431.4% |
| Ebitda Margin | 1350.3% | ▲1350.3% | ▲2367.6% |
| Operating Profit Margin | -1536.9% | ▼-1536.9% | ▲358.9% |
| Pretax Profit Margin | 1224.8% | ▲1224.8% | ▲2417.2% |
| Continuous Operations Profit Margin | 1223.1% | ▲1223.1% | ▲2415.8% |
| Net Profit Margin | 1223.1% | ▲1223.1% | ▲2415.8% |
| Bottom Line Profit Margin | 1152.5% | ▲1152.5% | ▲2412.9% |
| Current Ratio | 6.929 | ▲0.849 | ▲1.455 |
| Quick Ratio | 6.744 | ▲0.663 | ▲1.306 |
| Solvency Ratio | 1.238 | ▲2.176 | ▲2.006 |
| Cash Ratio | 2.653 | ▲1.244 | ▲0.863 |
| Price To Earnings Ratio | 3.933 | ▲7.526 | ▲4.452 |
| Price To Earnings Growth Ratio | -0.021 | ▼-0.114 | ▼-0.059 |
| Forward Price To Earnings Growth Ratio | -0.021 | ▼-0.114 | ▼-0.059 |
| Price To Earnings Diluted Ratio | 5.218 | ▲8.811 | ▲5.479 |
| Price To Earnings Diluted Growth Ratio | -0.032 | ▼-0.124 | ▼-0.067 |
| Price To Book Ratio | 1.753 | ▼-3.440 | ▼-1.420 |
| Price To Sales Ratio | 47.949 | ▲47.949 | ▲26.582 |
| Price To Free Cash Flow Ratio | -3.310 | ▲0.601 | ▼-1.085 |
| Price To Operating Cash Flow Ratio | -3.656 | ▲0.425 | ▼-1.316 |
| Debt To Assets Ratio | 0.114 | ▼-0.098 | ▼-0.015 |
| Debt To Equity Ratio | 0.157 | ▼-0.367 | ▼-0.153 |
| Debt To Capital Ratio | 0.136 | ▼-0.208 | ▼-0.094 |
| Long Term Debt To Capital Ratio | 0.047 | ▼-0.182 | ▼-0.008 |
| Financial Leverage Ratio | 1.379 | ▼-1.095 | ▼-1.111 |
| Working Capital Turnover Ratio | 0.045 | ▲0.045 | ▲0.001 |
| Operating Cash Flow Ratio | -2.581 | ▲0.796 | ▲1.070 |
| Operating Cash Flow Sales Ratio | -13.114 | ▼-13.114 | ▲2.151 |
| Free Cash Flow Operating Cash Flow Ratio | 1.105 | ▲0.061 | ▲0.060 |
| Debt Service Coverage Ratio | 4.917 | ▲10.504 | ▲42.794 |
| Interest Coverage Ratio | -23.917 | ▼-8.657 | ▲25.221 |
| Short Term Operating Cash Flow Coverage Ratio | -6.245 | ▲3.207 | ▼-3.106 |
| Operating Cash Flow Coverage Ratio | -3.057 | ▼-0.627 | ▲1.952 |
| Capital Expenditure Coverage Ratio | -9.571 | ▲13.330 | ▲89.346 |
| Dividend Paid And Capex Coverage Ratio | -9.571 | ▲13.330 | ▲89.346 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 2.871 | ▲6.903 | ▲3.619 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $279.1M | $228.6M | $107.1M | $24.2M | $33.5M | |
| Enterprise value | $225.6M | $228.3M | $98.0M | $17.6M | $9.9M | |
| EV / Sales | 38.76x | 0.00x | 28.01x | 12.46x | 3.30x | |
| EV / Op. cash flow | -2.96x | -4.08x | -2.65x | -0.41x | -0.15x | |
| EV / Free cash flow | -2.68x | -3.91x | -2.63x | -0.40x | -0.14x | |
| EV / EBITDA | 2.87x | -4.03x | -1.94x | -0.51x | -0.13x | |
| Net debt / EBITDA | -0.68x | 0.01x | 0.18x | 0.19x | 0.31x | |
| Current ratio | 6.93x | 6.08x | 4.15x | 6.83x | 3.39x | |
| Income quality | -1.07x | 0.88x | 0.68x | 1.09x | 0.77x | |
| Graham number | $10 | — | — | — | — | |
| Graham net-net | $3 | $1 | $0 | $2 | $3 | |
| Tax burden | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 95.0% | 107.1% | 100.8% | 101.9% | 104.5% | |
| Working capital | $175.3M | $84.3M | $42.3M | $45.3M | $39.7M | |
| Invested capital | $189.2M | $92.2M | $50.3M | $56.4M | $62.8M | |
| Return on assets | 32.4% | -58.5% | -84.7% | -61.8% | -106.7% | |
| Operating ROA | -54.5% | -74.3% | -73.5% | -70.8% | -77.9% | |
| Return on tangible assets | 32.4% | -58.5% | -84.7% | -61.8% | -108.6% | |
| Return on equity | 44.7% | -144.7% | -365.5% | -148.3% | -200.5% | |
| Return on invested capital | -44.0% | -64.8% | -91.4% | -87.5% | -138.7% | |
| Return on capital employed | -47.1% | -69.5% | -93.2% | -90.2% | -142.7% | |
| Earnings yield | 25.5% | -27.9% | -50.6% | -163.9% | -253.7% | |
| Free cash flow yield | -30.2% | -25.6% | -34.9% | -180.1% | -208.6% | |
| Capex / Op. cash flow | -10.4% | -4.4% | -0.9% | -0.3% | -6.3% | |
| Capex / Depreciation | 223.8% | 84.1% | 10.4% | 2.8% | 93.0% | |
| Capex / Sales | 137.0% | 0.0% | 9.5% | 9.2% | 138.4% | |
| SG&A / Sales | 1117.4% | 0.0% | 543.0% | 1220.4% | 721.5% | |
| R&D / Sales | 460.7% | 0.0% | 888.3% | 2048.4% | 1290.9% | |
| Stock comp / Sales | 185.2% | 0.0% | 136.2% | 215.8% | 297.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | |
| Days sales outstanding | 421d | 0d | 255d | 49d | 365d | |
| Days payables outstanding | 1880d | 432d | 423d | 1469d | 0d | |
| Operating cycle | 1730d | 0d | 255d | 49d | 365d | |
| Cash conversion cycle | -150d | -432d | -168d | -1420d | 365d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-02 Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-10-01 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-09-29 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-09-24 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
- 2026-09-22 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-09-22 Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
- 2026-09-22 Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a longer foundation-building period than a conventional drug because of the therapy''s individualized manufacturing process, limited shelf life and specialized treatment-center requirements.
- 2026-09-18 Abeona Stands to Collect Royalties After Ultragenyx''s FDA Approval — Here''s the Rest of the Week Abeona Therapeutics Inc. (NASDAQ:ABEO) had a busy week that included a new treatment center activation, an FDA approval for a drug the company licensed away and multiple fresh analyst ratings.
- 2026-09-18 Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona''s foundational R&D and clinical development efforts -
- 2026-09-17 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).